Comparison of Inhaled Iloprost and Nitric Oxide in Patients With Pulmonary Hypertension During Weaning From Cardiopulmonary Bypass in Cardiac Surgery: A Prospective Randomized Trial

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 22, Issue 3, 2008, Pages 406-413

  Winterhalter, Michael ^a   Simon, Andre ^a   Fischer, Stefan ^a   Rahe Meyer, Niels ^a   Chamtzidou, Nicoletta ^a   Hecker, Hartmut ^a   Zuk, Janusz ^a   Piepenbrock, Siegfried ^a   Strüber, Martin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

cardiac surgery; iloprost; nitric oxide; pulmonary hypertension

Indexed keywords

ETOMIDATE; FENTANYL; ILOPROST; NITRIC OXIDE;

ADULT; AGED; ANESTHESIA INDUCTION; ANGIOCARDIOGRAPHY; ARTICLE; ARTIFICIAL VENTILATION; CARDIOPULMONARY BYPASS; CENTRAL VENOUS PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEART LEFT ATRIUM PRESSURE; HEART OUTPUT; HUMAN; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; UNIVERSITY HOSPITAL;

ADMINISTRATION, INHALATION; AGED; CARDIOPULMONARY BYPASS; CARDIOVASCULAR SURGICAL PROCEDURES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES;

EID: 44149096954     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2007.10.015     Document Type: Article

References (58)

1. Goyal P., Kiran U., Chauhan S., et al. Efficacy of nitroglycerin inhalation in reducing pulmonary arterial hypertension in children with congenital heart disease. Br J Anaesth 97 (2006) 208-214
2. Sablotzki A., Starzmann W., Scheubel R., et al. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Can J Anaesth 52 (2005) 1076-1082
3. Roques F., Nashef P., Michel E., et al. Risk factors and outcome in European cardiac surgery: Analysis of the EuroSCORE multinational database of 19,030 patients. Eur J Cardiothorac Surg 15 (1999) 816-823
4. Sibbald W.J., and Driedger A.A. Right ventricular function in acute disease states: Pathophysiologic considerations. Crit Care Med 11 (1983) 339-345
5. Stobierska-Dzierzek B., Awad H., and Michler R.E. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 38 (2001) 923-931
6. Urabe Y., Tomoike H., Ohzono K., et al. Role of afterload in determining regional right ventricular performance during coronary underperfusion in dogs. Circ Res 57 (1985) 96-104
7. Vlahakes G.J., Turley K., and Hoffman J.I. The pathophysiology of failure in acute right ventricular hypertension: Hemodynamic and biochemical correlations. Circulation 63 (1981) 87-95
8. Augoustides J.G., and Ochroch E.A. Inhaled selective pulmonary vasodilators. Int Anesthesiol Clin 43 (2005) 101-114
9. Jeon Y., Ryu J.H., Lim Y.J., et al. Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients. Eur J Cardiothorac Surg 29 (2006) 952-956
10. Langer F., Wilhelm W., Tscholl D., et al. Intraoperative inhalation of the long-acting prostacyclin analog iloprost for pulmonary hypertension. J Thorac Cardiovasc Surg 126 (2003) 874-875
11. Denault A.Y., Lamarche Y., Couture P., et al. Inhaled milrinone: A new alternative in cardiac surgery?. Semin Cardiothorac Vasc Anesth 4 (2006) 346-360
12. Lamarche Y., Perrault L.P., Maltais S., et al. Preliminary experience with inhaled milrinone in cardiac surgery. Eur J Cardiothorac Surg 31 (2007) 1081-1087
13. Pepke-Zaba J., Higenbottam T.W., Dinh-Xuan A.T., et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338 (1991) 1173-1174
14. Kadosaki M., Kawamura T., Oyama K., et al. Usefulness of nitric oxide treatment for pulmonary hypertensive infants during cardiac anesthesia. Anesthesiology 96 (2002) 835-840
15. Lowson S.M. Inhaled alternatives to nitric oxide. Anesthesiology 96 (2002) 1504-1513
16. Walmrath D., Schneider T., Pilch J., et al. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 342 (1993) 961-962
17. Lowson S.M., Doctor A., Walsh B.K., et al. Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgery. Crit Care Med 30 (2002) 2762-2764
18. Kramm T., Eberle B., Guth S., et al. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardiothorac Surg 28 (2005) 882-888
19. Theodoraki K., Rellia P., Thanopoulos A., et al. Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. Can J Anaesth 49 (2002) 963-967
20. Fattouch K., Sbraga F., Bianco G., et al. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg 20 (2005) 171-176
21. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
22. Olschewski H., Walmrath D., Schermuly R., et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124 (1996) 820-824
23. Winterhalter M., Fischer S., Tessmann R., et al. Using inhaled iloprost to wean from cardiopulmonary bypass after implanting a left ventricular assist device. Anesth Analg 103 (2006) 515-516
24. Winterhalter M., Simon A., Fischer S., et al. Inhaled iloprost in lung transplantation: Can it avoid extracorporeal circulation in patients with severe pulmonary hypertension?. J Cardiothorac Vasc Anesth 20 (2006) 716-718
25. Galie N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25 (2004) 2243-2278
26. Solina A., Papp D., Ginsberg S., et al. A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth 14 (2000) 12-17
27. Schmid E.R., Bürki C., Engel M.H., et al. Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery. Anesth Analg 89 (1999) 1108-1115
28. Sablotzki A., Hentschel T., Gruenig E., et al. Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur J Cardiothorac Surg 22 (2002) 746-752
29. Schroeder R.A., Wood G.L., Plotkin J.S., et al. Intraoperative use of inhaled PGI(2) for acute pulmonary hypertension and right ventricular failure. Anesth Analg 91 (2000) 291-295
30. Higenbottam T.W., Butt A.Y., Dinh-Xaun A.T., et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 79 (1998) 175-179
31. Hoeper M.M., Olschewski H., Ghofrani H.A., et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 35 (2000) 176-182
32. Nashef S.A., Roques F., Michel P., et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 16 (1999) 9-13
33. Carrel T., Englberger L., Mohacsi P., et al. Low systemic vascular resistance after cardiopulmonary bypass: Incidence, etiology, and clinical importance. J Card Surg 15 (2000) 347-353
34. Steudel W., Hurford W.E., and Zapol W.M. Inhaled nitric oxide: Basic biology and clinical applications. Anesthesiology 91 (1999) 1090-1121
35. Atz A.M., Adatia I., and Wessel D.L. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 62 (1996) 1759-1764
36. Augoustides J.G., Culp K., and Smith S. Rebound pulmonary hypertension and cardiogenic shock after withdrawal of inhaled prostacyclin. Anesthesiology 100 (2004) 1023-1025
37. Grant S.M., and Goa K.L. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 43 (1992) 889-924
38. van Heerden P.V., Gibbs N.M., and Michalopoulos N. Effect of low concentrations of prostacyclin on platelet function in vitro. Anaesth Intensive Care 25 (1997) 343-346
39. Fattouch K., Sbraga F., Sampognaro R., et al. Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: A randomized, prospective, double-blind study. J Cardiovasc Med 7 (2006) 119-123
40. Fischer L.G., Van Aken H., and Bürkle H. Management of pulmonary hypertension: Physiological and pharmacological considerations for anesthesiologists. Anesth Analg 96 (2003) 1603-1616
41. Stein K.L., Breisblatt W., Wolfe C., et al. Depression and recovery of right ventricular function after cardiopulmonary bypass. Crit Care Med 18 (1990) 1197-1200
42. Roques F., Nashef S.A., Michel P., and EuroSCORE study group. Risk factors for early mortality after valve surgery in Europe in the 1990s: Lessons from the EuroSCORE pilot program. J Heart Valve Dis 10 (2001) 572-577
43. Reich D.L., Bodian C.A., Krol M., et al. Intraoperative hemodynamic predictors of mortality, stroke, and myocardial infarction after coronary artery bypass surgery. Anesth Analg 89 (1999) 814-822
44. Gaine S. Pulmonary hypertension. JAMA 284 (2000) 3160-3168
45. Schulze-Neick I., Li J., Reader J.A., et al. The endothelin antagonist BQ123 reduces pulmonary vascular resistance after surgical intervention for congenital heart disease. J Thorac Cardiovasc Surg 124 (2002) 435-441
46. Wagner F.D., Buz S., Knosalla C., et al. Modulation of circulating endothelin-1 and big endothelin by nitric oxide inhalation following left ventricular assist device implantation. Circulation 108 suppl 1 (2003) 278-284
47. Frostell C., Fratacci M.D., Wain J.C., et al. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 83 (1991) 2038-2047
48. Moncada S., Gryglewski R., Bunting S., et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263 (1976) 663-665
49. Scheeren T., and Radermacher P. Prostacyclin (PGI2): New aspects of an old substance in the treatment of critically ill patients. Intensive Care Med 23 (1997) 146-158
50. Loh E., Stamler J.S., Hare J.M., et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 90 (1994) 2780-2785
51. Haraldsson A., Kieler-Jensen N., Nathorst-Westfelt U., et al. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest 114 (1998) 780-786
52. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 (1997) 44-54
53. Kisch-Wedel H., Kemming G., Meisner F., et al. Effect of prostaglandin I2 analogues on left ventricular diastolic function in vivo. Eur J Pharmacol 517 (2005) 208-216
54. Adaikan P.G., and Kottegoda S.R. Prostacyclin analogues. Drugs Future 10 (1985) 765-774
55. Langer F., Wendler O., Wilhelm W., et al. Treatment of a case of acute right heart failure by inhalation of iloprost, a long-acting prostacyclin analogue. Eur J Anaesthesiol 18 (2001) 770-773
56. Olschewski H., Rose F., Schermuly R., et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 102 (2004) 139-153
57. Flondor M., Merkel M., Hofstetter C., et al. The effect of inhaled nitric oxide and inhaled iloprost on hypoxaemia in a patient with pulmonary hypertension after pulmonary thrombarterectomy. Anaesthesia 61 (2006) 1200-1203
58. Rimensberger P.C., Spahr-Schopfer I., Berner M., et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: Vasodilator capacity and cellular mechanisms. Circulation 103 (2001) 544-548